Suraksha Diagnostic Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Healthcare Services | Market Cap: ₹1.6K Cr
Suraksha Diagnostic Limited expects a consistent revenue growth of around 15% year-on-year for the next 2 to 3 years. Suraksha Diagnostic Limited expects a top-line revenue growth of around 15% year-on-year over the next 2 to 3 years.
From Suraksha Diagnostic Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹326
Market Cap
₹1.6K Cr
P/E Ratio
44.4
How does Suraksha Diagnostic Ltd rank in Healthcare Services?
Compare Suraksha Diagnostic Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹81 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
- →Suraksha Diagnostic Limited expects a consistent revenue growth of around 15% year-on-year for the next 2 to 3 years.
- →The number of tests and patient volumes are projected to grow, supported by new center additions (12 to 15 own centers plus PPP and Fetomat centers adding up to 18-20 total).
- →New centers contribute gradually with initial revenues around INR 90 lakhs for small centers and INR 1.5-2 crores for big centers in the first year.
- →Despite some quarter-to-quarter impacts (e.g., floods, delayed licenses), mature centers grow at approximately 10%.
- →The company anticipates margin expansion with EBITDA margin increasing by 1-2% annually due to operating leverage as new centers mature.
- →Growth is supported by scaling B2B business and genomic services with no negative long-term margin impact expected.
- →Market penetration in current and new geographies, including untapped regions like Northeast India, will fuel future growth.
📈 Profitability & Margins
- →Suraksha Diagnostic Limited expects a top-line revenue growth of around 15% year-on-year over the next 2 to 3 years.
- →EBITDA margins are projected to increase by 1% to 2% annually as the company benefits from scale and tighter cost control.
- →PAT (Profit After Tax) margins are also expected to improve by 1% to 2% each year.
- →Newer centers currently impact margins negatively but are expected to reach breakeven and contribute to improved overall profitability.
- →The company maintains a conservative growth approach but anticipates margin expansion driven by mature centers and operating leverage.
- →EPS showed improvement from INR3.43 in H1 FY25 to INR3.53 in H1 FY26, with expectations for continued growth aligned with revenue and margin improvement.
🏗️ Capital Expenditure Plans
- →The company plans to invest around INR 70 crores annually in opening new centers organically.
- →For FY26, they plan to add 12 to 15 new centers (5 big and 13 small centers in progress).
- →They have a fairly underleveraged balance sheet and can raise debt if needed, but currently, expansions are funded through internal accruals.
- →They are actively looking for inorganic growth opportunities through acquisitions, especially in new geographies with existing players.
- →The genomic lab setup is a key strategic investment aimed at increasing B2B business, without long-term margin impact.
- →They are developing software for loyalty schemes to incentivize repeat tests, to be operational in about two more quarters.
💰 Fundraising & Capital Structure
- →The company has a fairly underleveraged balance sheet.
- →Currently, all expansions and activities are being funded through internal accruals.
- →If required in the future, the company can always raise debt for growth.
- →No specific mention of any ongoing or planned equity fundraising was noted.
- →The company is actively looking for inorganic growth opportunities, which could potentially require funding.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Suraksha Diagno.'s management said in earlier quarters
Others in Healthcare Services this season
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
- Indegene Ltd (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
- Dr Lal Pathlabs Ltd (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…
- Health.Global (Q2 FY26)
Medium-term goal to realize Rs.4,000 crore revenue potential over 4-5 years from current Rs.2,200 crore at existing price points and optimized utilization. Key…
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q2 FY26 results?
Suraksha Diagnostic Limited expects a consistent revenue growth of around 15% year-on-year for the next 2 to 3 years. Suraksha Diagnostic Limited expects a top-line revenue growth of around 15% year-on-year over the next 2 to 3 years.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
The company plans to invest around INR 70 crores annually in opening new centers organically.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.